Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Heart and Circulation

Plain Language Summary: long-term effectiveness of ARRY-371797 in people with dilated cardiomyopathy caused by a faulty LMNA gene

This Plain Language Summary Publication from Future Cardiology describes the results of a long-term extension study on a medicine called ARRY-371797 in people with dilated cardiomyopathy caused by a faulty lamin A/C gene (also known as the LMNA gene), a condition which can lead to heart failure.

Read the full article here. 

The original article on which this Plain Language Summary of Publication is based is titled ‘Long-Term Efficacy and Safety of ARRY-371797 (PF-07265803) in Patients With Lamin A/C–Related Dilated Cardiomyopathy’ and was published in The American Journal of Cardiology. Read the original article here.  

Plain Language Summary: long-term survival in people being treated with tafamidis for transthyretin amyloid cardiomyopathy

This Plain Language Summary of Publication from Future Cardiology describes the results from an ongoing, long-term extension study looking at the survival rates of people with transthyretin amyloid cardiomyopathy being treated with tafamidis.

Read the full article here.

The original article on which this Plain Language Summary is based is titled ‘Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy’ and was published in Circulation: Heart Failure. Read the original article here.

Plain Language Summary of Publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene

This plain language summary from Future Cardiology describes the results of a study looking at the effects of a medicine called ARRY-371797 (also known as PF-07265803) in people with dilated cardiomyopathy caused by a faulty LMNA gene.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study’ and was published in Circulation: Genomic and Precision Medicine. Read the original article here.

Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment

The new plain language summary of publication in Future Cardiology uses information from the Fabry Registry to understand the effects of agalsidase beta treatment in women with Fabry disease.

Read the full article here.

The original article on which this summary is based is called ‘Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis’ and was originally published in the journal ESC Heart Failure. The original article can be read here.

How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary

A new plain language summary of publication published in Future Cardiology summarises some of the results of a study called ATTR-ACT. The article looked at the participants of the study who took placebo to learn how transthyretin amyloid cardiomyopathy progressed without treatment.

Read the article in full here.

Click here  to read the original article on which this summary is based.